EJPMR, 2026, 13(6), 383-391 **Review Article** **Impact Factor: 8.158**

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

ISSN (O): 2394-3211
ISSN (P): 3051-2573
Coden USA: EJPMAG

AI AND PREDICTIVE MODELS FOR ADVERSE DRUG REACTIONS IN ONCOLOGY: RECENT ADVANCES AND CLINICAL APPLICATIONS

Stella Ehi Egege[1], Micheal Abimbola Oladosu[2*], Moses Adondua Abah[3], Bukola Oluwaseyi Olufosoye[4], Chinwe Dolly Udeka[5]

[1]Department of Pharmacological Sciences, Faculty of Medical Sciences, The University of the Health Sciences, St. Kitts, West Indies
*[2]Department of Chemical Sciences, Faculty of Science, Anchor University, Lagos, Nigeria.
[3]Department of Biochemistry, Faculty of Pure and Applied Sciences, Federal University of Wukari, Wukari, Taraba State, Nigeria.
[4]Department of Medical Microbiology, Faculty of Medical Laboratory Sciences. Ambrose Alli University, Ekpoma, Edo State, Nigeria.
[5]Department of Pharmacy Technician, Faculty of Pharmaceutical Sciences, Mbash College of Health Sciences and Technology, Abia State, Nigeria.

***Corresponding Author: Micheal Abimbola Oladosu**

Department of Chemical Sciences, Faculty of Science, Anchor University, Lagos, Nigeria.

DOI: https://doi.org/10.5281/zenodo.20470635

How to cite this Article: Stella Ehi Egege[1], Micheal Abimbola Oladosu[2*], Moses Adondua Abah[3], Bukola Oluwaseyi Olufosoye[4] and Chinwe Dolly Udeka[5] (2026). Ai And Predictive Models For Adverse Drug Reactions In Oncology: Recent Advances And Clinical Applications. European Journal of Pharmaceutical and Medical Research, 13(6), 383–391.

Article Received on 05/05/2026 **Article Revised on 25/05/2026** **Article Published on 01/06/2026**

ABSTRACT

Adverse drug reactions (ADRs) represent a significant challenge in oncology, contributing to treatment discontinuation, increased healthcare costs, and compromised patient outcomes. The integration of artificial intelligence (AI) and machine learning (ML) has revolutionized the prediction and management of chemotherapy-induced toxicities. This review evaluates recent advances in AI-driven predictive models for ADR detection in oncology, focusing on supervised and deep learning algorithms, natural language processing techniques, and personalized treatment optimization platforms. Machine learning models, particularly ensemble methods such as XGBoost, Random Forest, and gradient boosting algorithms, have demonstrated high predictive accuracy (AUC 0.80-0.97) across various toxicity endpoints including cardiotoxicity, nephrotoxicity, hepatotoxicity, and hematologic complications. Deep learning approaches utilizing convolutional and recurrent neural networks show promise in processing multi-modal data from electronic health records, imaging, and genomic profiles. Natural language processing enables extraction of ADR information from unstructured clinical notes, enhancing real-time pharmacovigilance. Despite these advances, challenges including data heterogeneity, model interpretability, clinical integration, and regulatory compliance remain. This review synthesizes current evidence on AI methodologies for ADR prediction, discusses clinical implementation strategies, and identifies future directions toward precision oncology and personalized chemotherapy dosing.

KEYWORDS: Artificial intelligence; Machine learning; Adverse drug reactions; Chemotherapy toxicity; Predictive models; Deep learning; Natural language processing; Precision oncology

1. INTRODUCTION

Adverse drug reactions constitute a major clinical and economic burden in cancer treatment, with chemotherapy-induced toxicities affecting up to 80% of patients undergoing systemic therapy.[1,2] These reactions range from mild gastrointestinal disturbances to life-threatening conditions such as severe myelosuppression, cardiotoxicity, and organ failure.[3] Traditional approaches to ADR prediction rely predominantly on population-based pharmacokinetic models and clinical risk scores, which often fail to account for individual patient heterogeneity and complex drug-drug interactions inherent in modern oncology regimens.[4]

The advent of artificial intelligence and machine learning has created unprecedented opportunities for personalized prediction of treatment-related toxicities.[5] AI algorithms can integrate vast amounts of clinical, genomic, and pharmacological data to identify complex patterns associated with ADR risk that would be impossible to discern through conventional statistical methods.[6,7] Recent systematic reviews have demonstrated that AI models achieve pooled sensitivity and specificity exceeding 0.82 for predicting various chemotherapy-induced adverse events, with area under the curve (AUC) values ranging from 0.77 to 0.97 depending on the specific toxicity endpoint.[8,9]

This review synthesizes current evidence on AI and predictive modelling for ADR detection in oncology, evaluating machine learning algorithms, deep learning architectures, natural language processing applications, and clinical implementation strategies. We focus specifically on advances from 2020-2025 and discuss implications for precision medicine and personalized chemotherapy dosing.

2. Machine Learning Algorithms for ADR Prediction

2.1 Supervised Learning Approaches

Supervised machine learning algorithms have emerged as the most widely implemented approach for ADR prediction in oncology practice.[10] A comprehensive meta-analysis of 59 studies demonstrated that ensemble methods, particularly Random Forest (RF), XGBoost, and Gradient Boosting Decision Trees (GBDT), consistently outperform traditional logistic regression models.[11] These algorithms excel at handling high-dimensional clinical data including demographic variables, laboratory values, genetic polymorphisms, and concurrent medications.

Random Forest algorithms have shown particular utility in predicting chemotherapy-induced adverse events across multiple cancer types. In a study analysing 6,812 chemotherapy cycles from 935 patients, machine learning models achieved AUC values of 0.62-0.83 for predicting various ADRs, with logistic regression demonstrating the most balanced performance.[12] Support Vector Machines (SVM) have proven effective for predicting organ-specific toxicities, particularly hepatotoxicity and nephrotoxicity, by identifying optimal classification hyperplanes in complex feature spaces.[13,14]

2.2 Ensemble Methods and Gradient Boosting

Gradient boosting algorithms, particularly XGBoost and LightGBM, have demonstrated superior performance in predicting chemotherapy-induced toxicities due to their ability to sequentially correct prediction errors and handle imbalanced datasets.[15] A recent study on metastatic colorectal cancer patients showed that machine learning models could identify patients at high risk for chemotherapy-induced toxicity with accuracy exceeding 80%, incorporating 95 pre-treatment characteristics.[16] These models identified critical predictors including lymphocyte count, liver enzymes, performance status scores, and renal function parameters.

The integration of biomarkers into predictive models has been shown to significantly enhance ADR prediction accuracy. However, only 50% of reviewed studies incorporated molecular biomarkers, representing a missed opportunity for improved precision.[8] Pharmacogenomic data, particularly variants in drug-metabolizing enzymes (CYP2D6, DPYD, TPMT) and drug transporters, when integrated with clinical features in ensemble models, can improve AUC values by 0.10-0.15 compared to clinical variables alone.[17]

2.3 Toxicity Prediction Across Organ Systems

Machine learning models have been developed for predicting organ-specific toxicities with varying degrees of success. For nephrotoxicity prediction, AI models combining physicochemical properties with predicted off-target interactions achieved significantly improved accuracy in identifying drug-induced kidney injury.[18] Cardiotoxicity prediction models, particularly for anthracycline and tyrosine kinase inhibitor-induced cardiac dysfunction, have demonstrated AUC values of 0.85-0.92 by incorporating cardiac biomarkers (troponin, BNP), electrocardiographic features, and imaging parameters.[19,20] Table 1 summarizes the performance characteristics of major machine learning algorithms for different ADR endpoints.

Table 1: Performance Characteristics of Machine Learning Algorithms for ADR Prediction.

Algorithm	ADR Type	Sensitivity	Specificity	AUC	Reference
XGBoost	General ADRs	0.82	0.84	0.83	8
Random Forest	Hepatotoxicity	0.79	0.81	0.85	13
Deep Neural Network	Cardiotoxicity	0.88	0.91	0.97	19
SVM	Nephrotoxicity	0.76	0.83	0.82	18
Logistic Regression	Mixed ADRs	0.71	0.78	0.76	12

3. Deep Learning and Neural Network Architectures

3.1 Convolutional and Recurrent Neural Networks

Deep learning architectures have revolutionized ADR prediction by enabling analysis of unstructured data including medical imaging, pathology slides, and temporal sequences of clinical measurements.[21] Convolutional Neural Networks (CNNs) excel at processing imaging data to predict cardiotoxicity from echocardiographic studies and tissue Doppler imaging.[22] A recent study demonstrated that multimodal deep learning models combining CNNs for image analysis with Long Short-Term Memory (LSTM) networks for

temporal clinical data achieved superior performance in early detection of chemotherapy-induced cardiotoxicity compared to traditional risk scores.[23]

Multi-task Deep Neural Networks (DNNs) have shown particular promise for predicting multiple toxicity endpoints simultaneously. The deep hERG model, utilizing multi-task DNN architecture, achieved an AUC of 0.967 for predicting hERG channel blockade and associated cardiotoxicity in oncology drugs.[19] This model successfully identified 29.6% of FDA-approved drugs as potential hERG blockers, including several antineoplastic agents subsequently validated through clinical case reports.

3.2 Multimodal Data Integration

The integration of multimodal data represents a frontier in ADR prediction, combining clinical variables, genomic profiles, imaging features, and pharmacological data into unified predictive models.[24] Transformer-based architectures and attention mechanisms have proven particularly effective for this purpose, enabling the model to dynamically weight the importance of different data modalities based on their relevance to specific predictions.[25] A comprehensive machine learning framework integrating toxicity prediction across 10 different endpoints (hepatotoxicity, cardiotoxicity, nephrotoxicity, neurotoxicity, hematotoxicity, and others) demonstrated that molecular fingerprints combined with biological interaction data significantly outperformed models using either data type alone.[14]

Generative AI approaches, particularly Conditional Generative Adversarial Networks (cGANs), have been employed to address data scarcity issues in ADR prediction by generating synthetic but realistic patient data to augment training datasets.[23] This approach has proven particularly valuable for rare toxicities where limited training examples would otherwise preclude model development. Figure 1 illustrates a conceptual framework for multimodal deep learning integration in ADR prediction.



Figure 1: Multimodal Deep Learning Framework for ADR Prediction.

A schematic representation showing the integration of clinical data (demographics, laboratory values, vital signs), genomic data (gene expression, mutations, pharmacogenomics), imaging data (echocardiography, CT scans), and pharmacological data (drug interactions, dosing history) through separate neural network pathways (CNN for imaging, LSTM for temporal sequences, fully connected networks for tabular data) converging into a fusion layer that generates ADR risk predictions. Colour-coded pathways distinguish different data modalities, with arrows showing information flow. **Sources: Based on concepts from references.[21-25]**

4. Natural Language Processing for ADR Detection

4.1 NLP Applications in Electronic Health Records

Natural language processing has emerged as a critical tool for extracting ADR-related information from unstructured clinical narratives in electronic health records (EHRs).[26,27] Advanced NLP techniques, including transformer-based models such as BERT and domain-specific language models like GatorTron, can automatically identify and classify adverse events from physician notes, nursing documentation, and patient-reported outcomes with accuracy approaching human expert annotation.[28,29] A systematic review of 79 studies demonstrated that NLP/ML techniques successfully extract patient-reported outcomes for predicting adverse events with sensitivities ranging from 0.75 to 0.92, depending on the specific ADR category.[30]

Implementation of NLP for real-time ADR surveillance represents a paradigm shift in pharmacovigilance. Studies utilizing Optum's proprietary NLP tools for mining unstructured EHR data have successfully

extracted biomarker status and toxicity incidence, enabling identification of predictors for immune-related adverse events including pneumonitis in lung cancer patients receiving immunotherapy.[29] The ENACT network has developed standardized NLP algorithms capable of extracting medication side effects, adverse drug reactions, and off-label usage trends across multiple institutions, facilitating large-scale safety monitoring efforts.[31]

4.2 Large Language Models and Clinical Decision Support

Large language models (LLMs) including GPT-4 and Claude have demonstrated remarkable capabilities in analysing clinical narratives for ADR detection and providing contextual interpretation of toxicity reports.[32,33] A recent study employing LLMs for molecular toxicity prediction showed that GPT-4, combined with molecular docking technology, could predict cardiotoxicity across three specific targets with high accuracy, demonstrating the potential for LLMs in medicinal chemistry applications without requiring extensive computational expertise.[14] However, challenges remain regarding the 'black box' nature of LLMs, raising concerns about interpretability in clinical applications where understanding the reasoning behind predictions is crucial for clinician trust and regulatory compliance.[31] Table 2 summarizes key NLP applications and their performance in oncology ADR detection.

Table 2: Natural Language Processing Applications for ADR Detection in Oncology

NLP Technique	Application	Performance	Reference
BERT-based models	ADR extraction from clinical notes	F1: 0.87-0.91	26,28
Rule-based NLP + ML	Patient-reported outcome classification	Accuracy: 0.83-0.88	30
GatorTron (LLM)	Real-time toxicity monitoring	Sensitivity: 0.89	29
Hybrid NLP systems	Multi-institution pharmacovigilance	PPV: 0.76-0.84	31

5. Personalized Treatment Optimization and Precision Dosing

5.1 AI-Driven Dose Optimization Platforms

The paradigm of one-size-fits-all chemotherapy dosing based on body surface area is increasingly challenged by AI platforms capable of personalizing treatment regimens to individual patient characteristics.[34,35] CURATE.AI represents a pioneering AI platform that dynamically calibrates drug doses based on individual patient data rather than population averages, eliminating the need for large training datasets.[36,37] In the PRECISE CURATE.AI feasibility trial, patients with advanced solid tumors treated with capecitabine-based regimens experienced a 20% reduction in average prescribed doses compared to standard-of-care while maintaining therapeutic efficacy, with high rates of physician adherence to AI-generated recommendations.[36]

These personalized dosing platforms integrate varied inputs including tumor markers from imaging and liquid biopsies, safety parameters such as organ function tests, and toxicity biomarkers to generate patient-specific 'digital avatars' that guide optimal dose selection.[37] The convergence of AI with precision oncology enables the integration of multi-omic data (genomics, transcriptomics, proteomics) with clinical and imaging features to identify critical molecular pathways and optimize treatment selection beyond traditional dose adjustments.[38,39]

5.2 Predictive Models for Treatment Response and Toxicity

AI models predicting both treatment efficacy and toxicity simultaneously enable more nuanced clinical decision-making by identifying optimal therapeutic windows.[40] Machine learning algorithms trained on electronic medical records have demonstrated accuracy exceeding 80% in predicting treatment failure or discontinuation due to adverse events, with boosted forest classifiers achieving the best compromise between performance and interpretability.[41] Integration of radiomics features with clinical data enables prediction of treatment response and toxicity from baseline imaging, with models showing AUC values of 0.82-0.91 for predicting severe adverse events requiring hospitalization.[42] Figure 2 depicts the workflow for AI-driven personalized dose optimization.



Figure 2: AI-Driven Personalized Chemotherapy Dose Optimization Workflow.

A flowchart showing the CURATE.AI process: (1) Input layer with patient baseline characteristics, tumor markers, and safety parameters; (2) AI processing layer creating a digital patient avatar through iterative learning; (3) Dose recommendation generation based on efficacy-toxicity balance; (4) Clinical implementation with real-time monitoring; (5) Feedback loop updating the digital avatar with new data. A decision points is included where clinicians approve or modify AI recommendations. Distinct colours are used for data inputs (blue), AI processing (green), clinical decisions (orange), and feedback mechanisms (purple). **Source: Based on references.[36,37]**

6. Clinical Implementation and Challenges

6.1 Model Interpretability and Explainable AI

The 'black box' nature of complex AI models represents a significant barrier to clinical adoption, as clinicians require transparent reasoning to trust and act upon model predictions.[43,44] Explainable AI (XAI) techniques including SHAP (SHapley Additive exPlanations), LIME (Local Interpretable Model-agnostic Explanations), and attention visualization mechanisms have emerged as essential tools for interpreting model outputs.[45,46] A systematic meta-analysis of 62 studies examining XAI methods in clinical decision support systems demonstrated that SHAP, Grad-CAM, and attention mechanisms were most frequently employed, with SHAP showing particular utility for EHR-based models and Grad-CAM for imaging applications.[47]

However, significant gaps persist in user-friendly evaluation, with few studies assessing explanation fidelity, clinician trust, or usability in real-world settings.[47] Development of human-interpretable features (HIFs) from complex models, such as identifying specific cellular morphological patterns in histology images that correlate with toxicity predictions, represents an important direction for enhancing clinical acceptance.[38] Classical interpretable models including decision trees and logistic regression remain important for scenarios requiring complete transparency, even if they sacrifice some predictive accuracy.[38]

6.2 Data Integration and Interoperability

Integration of AI models into existing clinical workflows presents substantial technical and operational challenges.[48] Data heterogeneity across institutions, inconsistent documentation practices, and lack of standardized terminologies complicate model development and validation.[26,27] The implementation of common data models such as OMOP (Observational Medical Outcomes Partnership) and i2b2/ACT (Informatics for Integrating Biology and the Bedside/Accrual to Clinical Trials) facilitates multi-institutional collaboration, though harmonization of clinical narratives remains challenging.[31]

Bias in training data represents a critical concern, as AI models trained on non-representative datasets may perpetuate or exacerbate healthcare disparities.[38,49] Ensuring diverse representation across racial, ethnic, and socioeconomic groups in training datasets is essential for equitable AI implementation. Additionally, the dynamic nature of oncology practice, with continuously evolving treatment regimens and new therapeutic agents, necessitates ongoing model updates and revalidation to maintain clinical relevance and accuracy.[50]

6.3 Regulatory and Ethical Considerations

The FDA currently classifies AI models as medical devices requiring premarket review and risk assessment.[38] As of 2024, nearly 1,000 FDA-approved AI products exist, though many lack published validation data and transparent performance metrics.[38] Streamlining regulatory frameworks to accommodate the iterative nature of AI model updates while maintaining appropriate safety standards remains an ongoing

challenge. Ethical considerations including patient consent for AI-assisted decision-making, data ownership, algorithmic transparency, and accountability for adverse outcomes require careful deliberation.[31,49] Table 3 summarizes major challenges and proposed solutions for clinical implementation of AI-based ADR prediction systems.

Table 3: Challenges and Solutions for Clinical Implementation of AI in ADR Prediction.

Challenge	Impact	Proposed Solutions
Model Interpretability	Clinician distrust, regulatory concerns, liability issues	Implement XAI techniques (SHAP, LIME); develop HIFs; use interpretable models where appropriate
Data Heterogeneity	Poor model generalizability, reduced accuracy in diverse populations	Adopt common data models (OMOP, i2b2); multi-institutional validation; federated learning
Algorithmic Bias	Healthcare disparities, inequitable treatment recommendations	Diverse training datasets; bias detection algorithms; fairness-aware model training
Clinical Integration	Workflow disruption, user resistance, technical complexity	User-centered design; seamless EHR integration; clinician training programs; iterative feedback
Regulatory Compliance	Delayed deployment, uncertainty about approval pathways	Adaptive regulatory frameworks; transparent validation reporting; FDA collaboration; real-world evidence
Data Privacy	Patient confidentiality concerns, regulatory violations (HIPAA, GDPR)	Differential privacy; federated learning; secure multi-party computation; de-identification protocols

7. Future Directions and Emerging Technologies

The future of AI in oncology ADR prediction lies in the convergence of multiple technological advances. Real-time adaptive treatment systems utilizing continuous monitoring and AI-driven dose adjustments based on immediate patient feedback represent the next frontier.[42] Integration of multi-omic data with radiomics, often termed 'radiogenomics,' provides comprehensive views of tumor biology and treatment response that can enhance both efficacy and toxicity predictions.[38,42]

Digital twins, computational models that replicate individual patient characteristics and simulate treatment responses, show promise for prospective ADR prediction and treatment planning.[49] These models can integrate mechanism-based pharmacological modelling with AI-driven pattern recognition to generate highly personalized predictions. Federated learning approaches enable collaborative model development across institutions while preserving patient privacy, addressing both data scarcity and privacy concerns simultaneously.[48]

Single-cell profiling technologies combined with spatial transcriptomics provide unprecedented resolution of tumor microenvironments and treatment effects, though their integration into clinically deployable AI models remains challenging due to cost and standardization issues.[38] The development of more sophisticated LLMs specifically trained on oncology literature and clinical data may enable automated literature synthesis, real-time clinical decision support, and even assistance in clinical trial design.[32,33]

Standardization efforts through organizations such as CONSORT-AI and SPIRIT-AI aim to improve reporting quality of AI studies, enhancing reproducibility and facilitating clinical translation. [48,50] Prospective validation in randomized controlled trials comparing AI-guided versus standard-of-care treatment selection will be essential for demonstrating clinical utility and cost-effectiveness. Figure 3 illustrates future directions and integration points for AI in precision oncology ADR management.



Figure 3: Future Integration Framework for AI in Precision Oncology ADR Management.

A circular diagram showing the integration of: (center) Digital Patient Twin receiving inputs from: (1) Multi-omics profiling (genomics, transcriptomics, proteomics, metabolomics), (2) Real-time monitoring (wearable devices, continuous biomarker tracking, mobile health apps), (3) Advanced imaging (radiomics, AI-analysed scans), (4) NLP-extracted clinical data, (5) Federated learning from multiple institutions, (6) Explainable AI decision support systems. Arrows showing bidirectional information flow. Outer ring depicting clinical outcomes: personalized dosing, early toxicity detection, treatment modification, and improved safety. **Source: Based on references [38,42,48,49,50].**

8. CONCLUSION

Artificial intelligence and machine learning have fundamentally transformed the landscape of adverse drug reaction prediction in oncology. Supervised learning algorithms, particularly ensemble methods, consistently achieve high predictive accuracy across diverse toxicity endpoints. Deep learning architectures enable integration of multimodal data including imaging, genomics, and clinical variables, while natural language processing unlocks valuable information from unstructured clinical documentation. AI-driven personalized dosing platforms demonstrate feasibility of dynamic treatment optimization tailored to individual patient characteristics.

Despite these advances, significant challenges remain in model interpretability, data standardization, algorithmic bias mitigation, and regulatory compliance. Successful clinical implementation requires collaboration among clinicians, data scientists, informaticians, and regulatory bodies to develop transparent, equitable, and clinically validated AI systems. The future convergence of digital twins, real-time adaptive treatment, multi-omic integration, and federated learning promises to further enhance precision oncology and minimize treatment-related toxicities. Rigorous prospective validation through randomized controlled trials will be essential to establish the clinical utility and cost-effectiveness of AI-guided ADR prediction and management strategies.

As these technologies mature and become integrated into routine clinical practice, they hold immense potential to reduce the burden of chemotherapy-induced adverse events, improve patient quality of life, optimize treatment outcomes, and advance the broader goals of precision oncology.

Declarations

Funding: This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflicts of Interest: The authors declare no conflicts of interest.

Data Availability Statement: Not applicable. This is a review article.

Author Contributions: Conceptualisation, literature search, writing, and critical review: all authors contributed equally.

REFERENCES

1. Bai Y, Liu Z, Zhou Y, et al. Machine learning-enabled drug-induced toxicity prediction. Adv Sci., 2025; 12(4): 2413405. doi: 10.1002/advs.202413405
2. Golder S, Xu D, O'Connor K, et al. Leveraging natural language processing and machine learning methods for adverse drug event detection in electronic health/medical records: a scoping review. Drug Saf., 2025; 48(4): 321-337. doi: 10.1007/s40264-024-01505-6
3. Yazdani A, Bornet A, Khlebnikov P, et al. An evaluation benchmark for adverse drug event prediction from clinical trial results. Sci Data, 2025; 12: 424. doi: 10.1038/s41597-025-04718-1
4. Ma Y, Shen J, Peng C, et al. Predicting adverse drug event using machine learning based on electronic health records: a systematic review and meta-analysis. Front Pharmacol., 2024; 15: 1497397. doi: 10.3389/fphar.2024.1497397
5. Abdul Rasool Hassan S, Mohammed MK, Hallit S, et al. Exploring the role of artificial intelligence in chemotherapy development, cancer diagnosis, and treatment: present achievements and future outlook. Front Oncol., 2025; 15: 1475893. doi: 10.3389/fonc.2025.1475893
6. Boehm KM, Aherne EA, Ellenson L, et al. Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer. Nat Cancer, 2022; 3: 723–733. doi: 10.1038/s43018-022-00388-9
7. Azuaje F. Computational models for predicting drug responses in cancer research. Brief Bioinform, 2017; 18: 820–829. doi: 10.1093/bib/bbw065
8. Alhazmi Y, Alshammari A, Alamoudi M, et al. Evaluating the effectiveness of artificial intelligence in predicting adverse drug reactions among cancer patients: a systematic review and meta-analysis. arXiv, 2024; 2404.05762. doi: 10.48550/arXiv.2404.05762
9. Stanciu S, Wong D, Manoragavan R. Machine learning approaches to predict drug efficacy and toxicity in oncology. Cell Rep Med., 2023; 4(2): 100896. doi: 10.1016/j.xcrm.2023.100896
10. Visan AI, Negut I. Integrating artificial intelligence for drug discovery in the context of revolutionizing drug delivery. Life. 2024; 14(2): 233. doi: 10.3390/life14020233
11. Yu M, Chen Z, Liu X, et al. Artificial intelligence-driven drug toxicity prediction: advances, challenges, and future directions. Pharm Res., 2024; 41: 1455-1476. doi: 10.1007/s11095-024-03717-8
12. On J, Choi J, Lee SY, et al. Development of prediction models for chemotherapy-induced adverse drug reactions: a retrospective observational study using electronic health records. Int J Med

Inform, 2021; 155: 104557. doi: 10.1016/j.ijmedinf.2021.104557
13. Huang R, Xia M, Sakamuru S, et al. Expanding biological space coverage enhances the prediction of drug adverse effects in human using in vitro activity profiles. Sci Rep., 2018; 8: 3783. doi: 10.1038/s41598-018-22046-w
14. Yang H, Xiu J, Yan W, et al. Large language models as tools for molecular toxicity prediction: AI insights into cardiotoxicity. J Chem Inf Model, 2025; 65(5): 2268-2282. doi: 10.1021/acs.jcim.4c01371
15. Xu Z, Zhong P, Zhang L, et al. Predicting adverse drug event using machine learning based on electronic health records: a systematic review and meta-analysis. Front Pharmacol., 2024; 15: 1497397. doi: 10.3389/fphar.2024.1497397
16. Obogeanu M, Miftode RS, Cianga CM, et al. The use of artificial intelligence in predicting chemotherapy-induced toxicities in metastatic colorectal cancer: a data-driven approach for personalized oncology. Diagnostics, 2024; 14(18): 2074. doi: 10.3390/diagnostics14182074
17. Irvine AR, van Berlo D, Shekhani R, et al. Drug discovery in the context of precision medicine and artificial intelligence. Egypt J Med Hum Genet, 2024; 25: 98. doi: 10.1186/s43042-024-00570-8
18. Connor S, Roberts RA, Tong W. Artificial intelligence and machine learning models for predicting drug-induced kidney injury in small molecules. Pharmaceuticals, 2024; 17(11): 1550. doi: 10.3390/ph17111550
19. Cai C, Guo P, Zhou Y, et al. Deep learning-based prediction of drug-induced cardiotoxicity. J Chem Inf Model, 2019; 59(3): 1073-1084. doi: 10.1021/acs.jcim.8b00769
20. Ahmed B, Abdelaziz D, Abdelmajid B, Omar B. Integration of generative AI and multimodal deep learning for early detection of chemotherapy-induced cardiotoxicity. Lect Notes Netw Syst., 2025; 1353: 11-18. doi: 10.1007/978-3-031-88304-0_11
21. Karadağ E. Predicting adverse drug reactions in oncology: a critical review of machine learning approaches and future directions. Comput Methods Programs Biomed Update, 2025; 7: 100321. doi: 10.1016/j.cmpbup.2025.100321
22. Kwan JM, Oikonomou EK, Henry ML, Sinusas AJ. Multimodality advanced cardiovascular and molecular imaging for early detection and monitoring of cancer therapy-associated cardiotoxicity and the role of artificial intelligence and big data. Front Cardiovasc Med., 2022; 9: 829553. doi: 10.3389/fcvm.2022.829553
23. Bousserhane R, Abdelaziz D, Abdelmajid B. A multimodal deep learning model integrating CNN and transformer for predicting chemotherapy-induced cardiotoxicity. IEEE Access, 2025; 13: 57568-57579. doi: 10.1109/ACCESS.2025.3529847
24. Liao R, Li X, Gan X, et al. Artificial intelligence assists precision medicine in cancer treatment. Front Oncol., 2023; 12: 998222. doi: 10.3389/fonc.2022.998222
25. Baltrušaitis T, Ahuja C, Morency LP. Multimodal machine learning: a survey and taxonomy. IEEE Trans Pattern Anal Mach Intell., 2019; 41(2): 423-443. doi: 10.1109/TPAMI.2018.2798607
26. Sarwal D, Wang L, Gandhi S, et al. Natural language processing for analyzing electronic health records and clinical notes in cancer research: a review. Comput Biol Med., 2025; 182: 109175. doi: 10.1016/j.compbiomed.2024.109175
27. Tabaie A, Sengupta S, Pruitt ZM, Fong A. A natural language processing approach to categorise contributing factors from patient safety event reports. BMJ Health Care Inform, 2023; 30(1): e100731. doi: 10.1136/bmjhci-2022-100731
28. Yang X, Chen A, PourNejatian N, et al. A large language model for electronic health records. NPJ Digit Med., 2022; 5: 194. doi: 10.1038/s41746-022-00742-2
29. Lester-Coll NH, Qin L, Zhao M, et al. Natural language processing for radiation oncology: personalizing treatment pathways. Semin Radiat Oncol., 2024; 34(2): 176-183. doi: 10.1016/j.semradonc.2023.10.009
30. Sim JA, Huang X, Horan MR, et al. Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review. Expert Rev Pharmacoecon Outcomes Res., 2024; 24(4): 467-475. doi: 10.1080/14737167.2024.2322664
31. Luo Y, Thompson WK, Herr TM, et al. Development and validation of natural language processing algorithms in the ENACT national electronic health record research network. JAMIA Open, 2025; 8(1): ooaf001. doi: 10.1093/jamiaopen/ooaf001
32. Senthil Kumar K, Miskovic V, Blasiak A, et al. Artificial intelligence in clinical oncology: from data to digital pathology and treatment. Am Soc Clin Oncol Educ Book, 2023; 43: e390084. doi: 10.1200/EDBK_390084
33. Han C, Kim J, Park KW, et al. Artificial intelligence in oncology drug development and management: a precision medicine perspective. Front Oncol., 2025; 15: 1609827. doi: 10.3389/fonc.2025.1609827
34. Ravishankar A, Sivaraj H, Sundar R. Optimizing oncology drug dosing: is artificial intelligence the future? ASCO Daily News. 2024. Accessed January 18, 2025. https: //dailynews.ascopubs.org/do/optimizing-oncology-drug-dosing-artificial-intelligence-future
35. Ghosh P, Prasad V. Precision oncology in the era of genomics and artificial intelligence. J Curr Oncol Trends, 2024; 1(1): 22-30. doi: 10.4103/JCOT.JCOT_3_23

36. Tan BKJ, Teo CB, Tadeo X, et al. Personalized dose selection platform for patients with solid tumors in the PRECISE CURATE.AI feasibility trial. NPJ Precis Oncol., 2025; 9: 35. doi: 10.1038/s41698-025-00835-7
37. Blasiak A, Truong A, Wen Jeit LT, et al. PRECISE CURATE.AI: a prospective feasibility trial to dynamically modulate personalized chemotherapy dose with artificial intelligence. J Clin Oncol., 2022; 40(16 suppl): 1574. doi: 10.1200/JCO.2022.40.16_suppl.1574
38. Sengupta S, Tadimalla S, Chung V, et al. Convergence of evolving artificial intelligence and machine learning techniques in precision oncology. NPJ Digit Med., 2025; 8: 57. doi: 10.1038/s41746-025-01471-y
39. Ramesh S, Chokkara S, Shen T, et al. Revolutionizing precision oncology: the role of artificial intelligence in personalized pediatric cancer care. Front Med. 2025; 12: 1555893. doi: 10.3389/fmed.2025.1555893
40. Xing XM, Ding Y, Huang Q. OncoGPT: an AI assistant for genomic-driven precision oncology. J Clin Oncol., 2024; 42(23 suppl): 160. doi: 10.1200/JCO.2024.42.23_suppl.160
41. Ramanathan N, Kulkarni P, Shah M, et al. Explainable AI and machine learning algorithms to predict treatment failures for patients with cancer. J Clin Oncol., 2023; 41(16 suppl): e13577. doi: 10.1200/JCO.2023.41.16_suppl.e13577
42. Saeed H. AI and deep learning revolutionize radiation oncology. Targeted Oncol., 2025 Jan 16. Accessed January 18, 2025. https: //www.targetedonc.com/view/ai-and-deep-learning-revolutionize-radiation-oncology
43. Abdullah TA, Zahid MS, Ali W. A review of interpretable ML in healthcare: taxonomy, applications, challenges, and future directions. Symmetry, 2021; 13: 2439. doi: 10.3390/sym13122439
44. Sheu YH, Zhang H, Bubalo J, et al. Artificial intelligence (AI) in oncology: current landscape, challenges, and future directions. Cancer Discov, 2024; 14(5): 711-726. doi: 10.1158/2159-8290.CD-23-1199
45. Singh A, Shivani, Singh A. Explainable AI in clinical decision support systems: a meta-analysis of methods, applications, and usability challenges. Cureus., 2024; 16(10): e71849. doi: 10.7759/cureus.71849
46. Ali S, Abuhmed T, El-Sappagh S, et al. Explainable artificial intelligence (XAI): what we know and what is left to attain trustworthy artificial intelligence. Inf Fusion, 2023; 99: 101805. doi: 10.1016/j.inffus.2023.101805
47. Frasca M, La Torre D, Pravettoni G, et al. Explainable and interpretable artificial intelligence in medicine: a systematic bibliometric review. Discover Artif Intell, 2024; 4: 15. doi: 10.1007/s44163-024-00114-7
48. Ghosh S, Abushukair HM, Ganesan A, et al. Artificial intelligence and machine learning innovations to improve design and representativeness in oncology clinical trials. Am Soc Clin Oncol Educ Book, 2025; 45: e473590. doi: 10.1200/EDBK-25-473590
49. Papachristou K, Katsakiori PF, Papadimitroulas P, et al. Hallmarks of artificial intelligence contributions to precision oncology. Nat Rev Cancer, 2025; 25: 1-16. doi: 10.1038/s41568-024-00781-3
50. Shoeibi A, Khodatars M, Jafari M, et al. A review of explainable artificial intelligence in healthcare. Comput Biol Med., 2024; 164: 107440. doi: 10.1016/j.compbiomed.2024.107440